COMMUNIQUÉS West-GlobeNewswire

Spyre Therapeutics Announces Grants of Inducement Awards
03/10/2025
WALTHAM, Mass., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, dose [...]
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
03/10/2025
DALLAS, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies [...]
argenx announces Extraordinary General Meeting of Shareholders on November 18, 2025
03/10/2025
October 3, 2025 Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced [...]
Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03/10/2025
CAMBRIDGE, Mass., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on September 19, 2025, the [...]
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
03/10/2025
NEW YORK, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on October 1, 2025 the Company [...]
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
03/10/2025
PALO ALTO, Calif., Oct. 03, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that on [...]
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03/10/2025
CAMBRIDGE, Mass., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today [...]
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03/10/2025
WESTLAKE VILLAGE, Calif., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, [...]
Cosmos Health Expands Sky Premium Life Into $1Bn+ Kuwait Market; Signs Exclusive Distribution Agreement With Diyar United and Secures Initial Purchase Order of Over 65,000 Units
03/10/2025
CHICAGO, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced that its subsidiary, [...]
Press release: Transparency Notification from Shareholder
03/10/2025
Transparency Notification from Shareholder Ghent, Belgium – 3 October 2025 – Sequana Medical NV (Euronext Brussels: SEQUA) (the " Company " or " Sequana Medical "), a pioneer in the treatment of drug-resistant fluid [...]
Smith+Nephew announce latest scientific data supporting new ALLEVYN™ COMPLETE CARE 5-Layer Foam Dressing for pressure injury prevention
03/10/2025
Smith+Nephew (NYSE:SNN; LSE:SN), the global medical technology business, is pleased to announce exciting new data from Professor Amit Gefen and his research group published in the International Wound Journal , 1 [...]
Mesa Laboratories, Inc. to Announce Second Quarter Results on November 6, 2025
03/10/2025
LAKEWOOD, Colo., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) will issue a press release with financial results for the second quarter of fiscal year 2026 following market close on Thursday, [...]
Frontier Medicines Announces Publication in Structure Highlighting Novel E3 Ligase DCAF2 can be Harnessed for Targeted Protein Degradation
03/10/2025
- First report of high-resolution structures of DCAF2 - - Frontier™ Platform key to discovering covalent ligands to selectively target DCAF2 - BOSTON and SOUTH SAN FRANCISCO, Calif., Oct. 03, 2025 (GLOBE NEWSWIRE) -- [...]
MESA LABS DECLARES QUARTERLY DIVIDEND
03/10/2025
Lakewood, Colo., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa” or the “Company”) today announced that its Board of Directors has declared a regular quarterly dividend of $0 [...]
Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting
03/10/2025
WATERTOWN, Mass., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated [...]
Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting
03/10/2025
WALTHAM, Mass., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living [...]
BioAtla to Present Clinical Data for Mecbotamab Vedotin (BA3011) in Soft Tissue Sarcoma at SITC 2025
03/10/2025
SAN DIEGO, Oct. 03, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB) , a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics using its [...]
Anathapindika Health’s Detoxifying Supplements Are Headed to Retailers in the US
03/10/2025
The Company’s Name Comes From Its Root Cause: to Provide Effective, Natural Solutions to Those Battling Health Issues. Soon, American Consumers Will Have Access to Those Solutions. Fort Lauderdale, FL, Oct. 03, 2025 ( [...]
Enara Bio to Reveal DARKFOX, a Novel Cancer-Specific Dark Antigen with Broad-Ranging Therapeutic Potential, in Oral Presentation at SITC 2025
03/10/2025
Oxford, United Kingdom – October 3, 2025. Enara Bio , a biopharmaceutical company pioneering the discovery of novel Dark Antigens® and the development of bispecific T cell engagers for solid tumors, will present two [...]

Pages